Clover Health Investments, Corp. CLOV shares are trading higher Tuesday. A recent analyst price target change and a quarterly report were two of the catalysts moving the stock during the month.
What To Know: Clover Health Investments reported second-quarter results earlier in the month. The company reported quarterly sales of $513.63 million which beat the analyst consensus estimate of $490.82 million, a 39.34% decrease over sales of $846.70 million the same period last year.
The company also issued full-year 2023 EBITDA guidance in a range between losses of $70 million and $120 million, versus the previous estimate of losses between $125 million and $175 million.
Clover also rose after Citigroup analyst Jason Cassorla maintained the company with a Neutral and raised the price target from $1 to $1.5 on Aug. 11.
The stock is up 43.85% over the past three months.
Related Link: Why BigBear.ai Stock Popped Today
CLOV Price Action: Shares of CLOV were up 12.2% at $1.38 at the time of publication, according to Benzinga Pro.
Image by Darko Stojanovic from Pixabay
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
